Ablative Fractional Laser Beneficial for C-Section Scars

Share this content:
Ablative Fractional Laser Beneficial for C-Section Scars
Ablative Fractional Laser Beneficial for C-Section Scars

TUESDAY, Nov. 15, 2016 (HealthDay News) -- Ablative fractional laser (AFXL) treatment is beneficial for patients with cesarean section (C-section) scars, according to a study published online Nov. 8 in Lasers in Surgery and Medicine.

Katrine E. Karmisholt, M.D., from the University of Copenhagen in Denmark, and colleagues conducted a randomized intra-individual split-scar trial with three sessions of AFXL-treatments for mature C-section scars. Eleven of 12 patients completed the study and underwent evaluations after one, three, and six months of follow-up.

The researchers found that compared with control scars, AFXL-treated scars were significantly improved in pliability (Patient and Observer Scar Assessment Scale [POSAS], P = 0.01) and smoother in surface relief (POSAS, P = 0.03) at one-month follow-up. Overall scar appearance was dominated by transient erythema and hyperpigmentation at one to three months, confirmed by reflectance measurements. AFXL-treated scars improved on POSAS total score at six-month follow-up, although not significantly (P = 0.06). Significant improvement was seen for AFXL-treated scars versus controls on blinded photo-evaluation (P = 0.02). New dermal collagen and elastic fibers were indicated in histology on AFXL-treated scars. Most patients (64 percent) favored subsequent AFXL-treatment of their untreated control tissue at six-month follow-up.

"Scar remodeling is initiated one month after AFXL treatment, but overall scar improvement is concealed until laser-induced color changes resolve," the authors write. "At six-month follow-up, the benefit of AFXL treatment on C-section scars emerges."

One author disclosed financial ties to Lumenis, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »